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Abstract Pluripotent stem cells (PSCs), such as embryonic
stem cells or induced pluripotent stem cells are a promising
source of cells for regenerative medicine as they can
differentiate into all cell types building a mammalian body.
However, protocols leading to efficient and safe in vitro
generation of desired cell types must be perfected before
PSCs can be used in cell therapies or tissue engineering.
In vivo, i.e. in developing mouse embryo or teratoma, PSCs
can differentiate into skeletal muscle, but in vitro their
spontaneous differentiation intomyogenic cells is inefficient.
Numerous attempts have been undertaken to enhance this
process. Many of them involved mimicking the interactions
occurring during embryonic myogenesis. The key regulators
of embryonic myogenesis, such as Wnts proteins, fibroblast
growth factor 2, and retinoic acid, have been tested to
improve the frequency of in vitromyogenic differentiation of
PSCs. This review summarizes the current state of the art,
comparing spontaneous and directed myogenic differentiation
of PSCs as well as the protocols developed this far to
facilitate this process.
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Introduction
Pluripotent stem cells (PSCs) are a valuable potential
source of various cell types for regenerative medicine as
they are able to differentiate into all cell types building a
mammalian body. Importantly, PSCs can be easily
expanded in vitro and have the capacity to undergo
unlimited cell divisions, retaining their pluripotency.
Among currently available PSCs are embryonic carcinoma
cells (ECCs; Kahan and Ephrussi 1970; Rosenthal et al.
1970); embryonic stem cells (ESCs; Evans and Kaufman
1981; Martin 1981), epiblast stem cells (EpiSCs; Brons
et al. 2007), recently derived region specific epiblast stem
cells (rsEpiSCs; Wu et al. 2015), and induced pluripotent
stem cells (iPSCs; Takahashi and Yamanaka 2006).
However, only ESCs and iPSCs are considered as candidates
for therapeutic approaches. For many years ESCs were
derived from the inner cell mass of blastocysts, i.e. at
3.5 day of mammalian development, a process that
inevitably leads to embryo destruction. For this reason
ESCs sparked public discussion and ethical controversy,
putting in question their potential use in regenerative
medicine. However, in 2006 a new method of ESC
derivation was proposed by Klimanskaya and co-workers,
who used a single blastomere isolated from the embryo
without disturbing further development (Klimanskaya et al.
2006). At the same time, the ground-breaking experiments
involving overexpression of Oct4, Sox2, Klf4, and c-myc in
mouse and human fibroblasts led to the generation of the
first iPSCs, giving the opportunity for PSC derivation from
non-embryonic (i.e. fetal or adult) cells (Takahashi and
Yamanaka 2006; Takahashi et al. 2007). In recent years,
significant progress in iPSC technology has been made,
enabling reprogramming of different somatic cells to a
pluripotent state in a safe way, i.e. using non-viral and
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transgene-free methods (for review see Lin and Wu 2015;
Seki and Fukuda 2015). Along with the already mentioned
methods of ESC derivation, these achievements resurrected
the expectations for use of PSCs in regenerative medicine.
In February
2015 Schwartz and co-workers summarized the results of
a first clinical trial during which PSC-derivatives were
used. During experimental therapy, patients suffering
from either age-related macular degeneration (Clinical
Trials.gov NCT01344993) or Stargardt’s macular dystrophy
(ClinicalTrials.gov NCT01345006) received subretinal
injections of retinal pigment epithelium cells derived from
human ESCs. Twenty-two months of follow up revealed
that visual acuity improved significantly in 10 of 18
patients and to a lesser extent in the next seven patients
(Schwartz et al. 2012). Currently, several other clinical
trials based on PSC transplantation are ongoing
(ClinicalTrials.gov; for review see Kimbrel and Lanza
2015). Thus, application of PSC-derivatives in regenerative
medicine can be achieved.
Spontaneous multidirectional differentiation of PSCs
occurs in vivo, e.g. when these cells are injected into
morula or blastocyst, they contribute to all tissues in the
formed chimera (for review see Tarkowski 1998).
Derivatives of all three germ layers can also be found in
teratomas formed by differentiating PSCs after their
transplantation either into immunologically privileged sites
such as kidney capsule or testis or under the skin of
immunodeficient mouse recipients (for review see Grabowska
et al. 2012a). In vitro PSC differentiation can be induced by
their culture in suspension what leads to the formation of so
called embryoid bodies (EBs), three-dimensional aggregates
in which cells differentiate into three germ layers: ecto-,
endo-, and mesoderm. When placed in culture dishes, EBs
adhere and form outgrowths composed of different types of
differentiating cells. Under such conditions some cell
types, such as cardiomyocytes or neurons, were shown to
arise with high frequency while others, for example
skeletal myoblasts, are rare (for review see Guan et al.
1999; Grivennikov 2008; Murry and Keller 2008). Since
efficient generation of myogenic cells is essential for
designing cell therapies for dysfunctional muscles, many
attempts have been made to improve techniques of PSC
myogenic differentiation.
Skeletal muscle has the ability to regenerate after
injuries occurring as a result of intense physical training or
development/progression of skeletal muscle diseases, such
as muscular dystrophies (e.g. Duchenne muscular dystrophy,
DMD). This ability relies on the presence of satellite
cells, i.e. muscle specific stem cells which differentiate to
skeletal myoblasts (for review see Moraczewski et al.
2008; Scharner and Zammit 2011; Yablonka-Reuveni
2011). Differentiation and fusion of myoblasts lead to the
formation of multinucleated myotubes, and finally myofibers,
reconstructing skeletal muscle. Importantly, due to their
ability to self-renew, the population of satellite cells
becomes restored in regenerated muscle. However, in the
case of reoccurring muscle injuries observed during
progression of muscular dystrophies, satellite cells fail to
efficiently renew their population as they are constantly
activated and undergo repeating divisions without the
gaps necessary to return to the quiescent stem cells state
(for review see Ciemerych et al. 2011). This eventually
leads to the exhaustion of the satellite cells population,
which can also occur as a result of substantial tissue loss
after tumor recession. Regardless of the original cause,
the depletion of satellite cells results in the impairment of
muscle structure and functionality, leading to physical
disability and respiratory failure which can be fatal for
patients.
Transplantation of cells that could support or replace
satellite cells is being considered as a cell therapy for
dysfunctional skeletal muscles. Pioneering experiments
involved satellite cells and myoblasts derived from them.
Due to the low number of satellite cells as well as difficulties
in their isolation and propagation in vitro this approach
turned out to be an inefficient solution. Moreover, results of
clinical trials involving myoblast transplantations in
patients suffering from muscular dystrophies were
unsatisfactory because of poor survival and migration of
transplanted cells within the recipient tissue (for review see
Bajek et al. 2015; Partridge and Morgan 2014). Therefore
other sources of cells, including PSCs, have been considered
for cell therapy of skeletal muscles. PSCs are a promising
choice for such therapy not only because of their ability to
differentiate into myogenic cells, but also due to their high
proliferation potential. Skeletal muscle is the most abun-
dant human tissue so successful cell therapy for disorders
affecting all muscles will require large number of cells for
transplantation.
Spontaneous versus directed myogenic
differentiation of PSCs
During embryo development or teratoma formation, PSCs
generate skeletal muscle, whichmeans that they havemyogenic
potential. In 1994 Rohwedel and co-workers obtained the
first in vitro PSCs-derived cells characterized by the
expression of muscle regulatory factors (MRFs), which are
transcription factors that play a key role in establishing the
identity of myogenic cells as discussed below. Cells
expressing MRFs, i.e. Myf5, MyoD, and myogenin were
identified in 7-day-old outgrowths obtained from EBs
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formed by differentiating mouse ESCs (Rohwedel et al.
1994). However, subsequent studies revealed that myogenic
markers such asMyoD ormyogenin are expressed at very low
level in ESCs, even after 10 days of their differentiation in
EBs (Darabi et al. 2008). Abundant numbers of functional
skeletal myoblasts were obtained only when forced expression
of essential myogenic genes such as Pax3 or Pax7 was
induced inmouse ESCs or iPSCs (Darabi et al. 2008, 2011a, b).
Pax3 and Pax7 genes are crucial for proper skeletal
muscle formation during embryogenesis (for review see
Buckingham and Rigby 2014). This multistep process
involves inter alia generation of skeletal muscle precursor
cells, their conversion into myoblasts, which then
differentiate and fuse, forming the multinucleated myofibers,
serving as a basic structural and functional skeletal
muscle unit. In mouse embryo, which serves as a model
of mammalian development, myogenesis is initiated at
the 8th day of development (Fig. 1). At this time paraxial
mesoderm, localized along axial structures of the embryo
such as notochord and neural tube, divides into segments
called somites. Next, two compartments are formed: the
sclerotome, which serves as a source of embryo cartilage
and bone, and the dermomyotome from which the
smooth muscles, blood vessels, derm, and muscles of the
body originate (Fig. 1). Generation and differentiation of
somites is controlled by morphogens released by the structures
adjacent to the somites. The notochord produces Sonic
hedgehog (Shh), the neural tube and surface ectoderm
secrete Wnts proteins and lateral mesoderm synthesizes
bone morphogenetic protein 4 (BMP-4). These factors,
together with fibroblast growth factor (FGF) and retinoic
acid (RA) establish polarity and pattering of the somites (for
review see Aulehla and Pourquie 2010; Bentzinger et al.
2012). While the dermomyotome serves as a source of trunk
and limb muscles, the head muscles originate from cranial
mesoderm (for review see Comai and Tajbakhsh 2014). In
the early stage of embryonic myogenesis the first committed
myogenic cells originating from the lips of the dermomyotome
form the primitive structure called myotome. Next, in the
central part of the dermomyotome, cells expressing Pax3
and Pax7 appear. Since these cells extensively proliferate
and serve as a source of both myoblasts and satellite cells,
they are called muscle precursor cells (MPCs; Fig. 1).
Although formation of muscles in different anatomical
Fig. 1 Outline of myogenesis in the mouse embryo. During
embryogenesis, skeletal muscles are formed from paraxial mesoderm
which divides into somites, i.e. mesodermal cell aggregates localized
along the axial structures of the embryo such as neural tube and
notochord. Somites differentiate into dermomyotome and sclerotome.
Dermomyotome serves as a source of cells producing dermis and
skeletal muscle while elements of the embryo skeleton develop from
the sclerotome. Muscle precursor cells (MPCs) appear in the central
part of the dermomyotome. Next, two waves of myoblasts formation
occur (marked I and II). Differentiation and fusion of myoblasts lead
to the formation of primary (purple) and secondary (blue)
multinucleated myotubes and myofibers. Eventually, at the 17th day
of development, satellite cells (green)—skeletal muscle stem cells—
appear in skeletal muscle (marked III). Selected stages of embryonic
myogenesis and the key myogenic regulators are indicated in the boxes
under the timeline (dpc—days post coitum)
J Muscle Res Cell Motil (2015) 36:363–375 365
123
regions of the embryo (i.e. head, trunk, limbs) is controlled
by different sets of genes (for review see Comai and
Tajbakhsh 2014), Pax3 and Pax7 act as critical upstream
regulators of trunk and limb muscle development, as
manifested by the phenotype of double Pax3/Pax7 knockout
mice lacking these muscles (Relaix et al. 2005; Kassar-
Duchossoy et al. 2005). Pax3 is also critical for migration of
MPCs from the somites to more distant sites of myogenesis
such as diaphragm, tongue, and limb buds (Bober et al.
1994; Goulding et al. 1994; Relaix et al. 2004). Moreover, it
has been shown that Pax genes are essential for cell survival
and proliferation during embryonic myogenesis (for review
see Borycki and Emerson 1997; Relaix et al. 2004). The key
role of Pax genes in myogenesis is also supported by the
fact that these transcription factors direct cells into the
myogenic program, acting as upstream regulators of MRFs.
It has been shown that Pax3 directly activates expression of
Myf-5 in somites and limbs (Bajard et al. 2006; Himeda
et al. 2013; Sato et al. 2010; Tajbakhsh et al. 1997) and
promotes expression of MyoD via Pitx2 (L’Honore et al.
2010).
During embryonic myogenesis MRFs, i.e. Myf-5,
MyoD, Mrf4, and myogenin, are expressed under strict
temporal and spatial control. Key findings on MRFs came
from knock-out mice analysis that revealed hierarchical
relationship between these factors as well as differences in
the specific roles they play during myogensis (for review
see Comai and Tajbakhsh 2014). Myf-5, MyoD, and Mrf4
were shown to act as determination genes promoting
progression of MPCs to myoblasts. Individually, these
MRFs can partially compensate for defects in the other
MRFs as single knock-out mice were characterized only by
delay in this process while triple mutants completely
lacked any myoblasts and myofibers (Braun et al. 1992;
Rudnicki et al. 1993; Tajbakhsh et al. 1997; Kassar-Du-
chossoy et al. 2004). The last of MRFs—myogenin—acts
downstream of the other MRFs and plays a unique role in
driving terminal differentiation of myoblasts into myotubes
and myofibers (Hasty et al. 1993; Nabeshima et al. 1993;
Venuti et al. 1995). As a result of MRF activity, muscle
specific microRNAs (Sweetman et al. 2008; Rao et al.
2006) or muscle specific genes such as myosin (Asakura
et al. 1993) are activated, establishing the proper architecture
and functionality of skeletal muscle. Last but not least, at
approximately the 17th day of development, basal lamina
envelops myofibers making the satellite cells accompanying
each myofiber visible for the first time (Fig. 1). As men
tioned before, satellite cells serve as a source of myoblasts
in growing and regenerating muscle. Their role as the
long-term muscle stem cells population is maintained by
Pax7 which prevents the premature differentiation and
exhaustion of these cells in juvenile and adult muscles (for
review see Buckingham and Rigby 2014; Comai and
Tajbakhsh 2014).
Spontaneous in vitro differentiation of PSCs into
myogenic cells occurs at an extremely low frequency (for
review see Grabowska et al. 2012a). However, various
approaches to enhance PSC differentiation have been
tested. As mentioned above, overexpression of key
myogenic regulators such as Pax3 or Pax7 led to the
efficient differentiation of PSCs into myogenic cells
(Darabi et al. 2008, 2011a, b). In all of these studies PSCs
(overexpressing Pax3 or Pax7) were first differentiated in
EBs and then cultured in the outgrowths. Cells expressing
PDGFaR, the marker of the paraxial mesoderm, and
negative for Flk1, the marker of lateral plate mesoderm
which serves as a source of hematopoietic cells (Sakurai
et al. 2006), were FACS sorted after 5 days of EB culture.
After additional 7 days of culture, cells were able not only
to express MRFs and other muscle specific proteins such
as Pax7 and myosin heavy chains (MyHC), but most of
them (from 78 % to 84 %, depending on the study) fused
and formed multinucleated myotubes (Darabi et al. 2008,
2011a, b). Since proper development of skeletal muscle as
well as their postnatal growth and regeneration depend on
ability of myoblasts to fuse with each other (for review
see Abmayr and Pavlath 2012), this feature is key for the
functionality of myogenic cells. Even more importantly,
cells positive for PDGFaR and negative for Flk1 were
also functional in vivo. When transplanted to injured or
dystrophic muscle they were able to participate in muscle
reconstruction as well as to settle the satellite cell niche,
which is prerequisite for long-term and successful cellular
therapy for dysfunctional skeletal muscles. Functionality
of transplanted cells was also confirmed by the improvement
of contractile properties of the muscles injected with cells
(Darabi et al. 2008, 2011a, b). Finally, the therapeutic
value of PSC-derived myogenic cells was underlined by
their ability to settle injured muscle not only after intramuscular
injection, but also after systemic transplantation (Darabi
et al. 2008, 2011b). This is of great importance as many
skeletal muscle diseases affect the entire body so the ability
of systemically transplanted cells to migrate and settle in
different groups of muscles is important to obtain
therapeutic effect. However, it should be noted that
although studies by Darabi and co-workers undeniably
showed that PSCs can be efficiently converted into
functional myogenic cells, genetically modified cells can
be used in skeletal muscle disease therapy only if they are
clinically safe, i.e. the integrity of their genome is preserved.
To achieve this, genetic cell modification must be
achieved by integration-free methods or targeted
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genome editing followed by the precise assessment of
cellular genome stability. Another approach to induce
differentiation of PSCs into desired cell type relies on the
application of proper environmental cues. This can be
achieved inter alia by the culture of PSCs in the presence
of tissue specific cells or in media supplemented with
factors involved in in vivo development (for review see
Cohen and Melton 2011). For example, the culture of
human ESCs in the presence of keratinocyte growth factor
(KGF), hedgehog signaling inhibitor, and RA led to the
their efficient differentiation into functional insulin
producing b-pancreatic cells (Pagliuca et al. 2014). Activation
of the Wnt signaling pathway followed by the culture of
cells in medium supplemented with L-ascorbic acid
2-phosphate resulted in the efficient generation of
cardiomyocytes (Burridge et al. 2014). Numerous attempts
have been also undertaken to promote myogenic differentiation
of PSCs. They involved co-culture, differentiation in EBs,
and monolayer-based experiments.
Co-culture-based methods of PSC myogenic
differentiation
Certain types of stem cells can be induced to undergo
myogenic differentiation when cultured in the presence of
myoblasts or in myoblasts-conditioned medium. This myogenic
induction have been shown for mesenchymal stem cells
derived from adipose tissue (Di Rocco et al. 2006; Vieira
et al. 2008), mesenchymal stem cells isolated from
umbilical cord connective tissue, i.e. Wharton’s jelly
(Grabowska et al. 2012b), and cells expressing AC133
isolated from peripheral blood (Torrente et al. 2004). All
these cells were able to fuse with differentiating myoblasts
and form hybrid myotubes, although with different
frequencies: adipose-derived stem cells—0.2 % (Di Rocco
et al. 2006), AC133 expressing cells—0.3 % (Torrente
et al. 2004), and Wharton’s jelly mesenchymal stem
cells—15 % (Grabowska et al. 2012b). Interestingly,
adipose-derived stem cells were also shown to be able to
undergo fusion-independent myogenic differentiation as
revealed by the expression of Pax7 and MRFs (Di Rocco
et al. 2006). Thus, factors present in media used for
myoblasts culture or conditioned by myoblasts are
sufficient to promote expression of muscle specific factors
in these cells (Di Rocco et al. 2006; Vieira et al. 2008). In
addition, AC133 expressing cells could be induced to
express MRFs and form myotubes when cultured in the
presence of fibroblasts secreting Wnt7a, a factor controlling
myogenesis (Torrente et al. 2004).
As far as PSCs are concerned, analysis of mouse ESCs
showed that when co-cultured with myoblasts, they participated
in the formation of hybrid myotubes with 1 % frequency
(Archacka et al. 2014). However, ESCs were not able to
undergo myogenic differentiation in a fusion-independent
way. MRFs were found only in the nuclei of ESCs which
fused with myoblasts, but not in those cells only exposed to
myoblast-conditioned medium (Archacka et al. 2014). The
presence of MyoD in the nuclei of ESCs cultured in the
myoblast-conditioned medium was reported only when
these cells were first induced to undergo differentiation by
long term co-culture with mouse OP9 stromal cells
(Barberi et al. 2005). After 40 days of culture, 5 % of cells
expressed CD73, a marker of mesenchymal stem cells and
paraxial mesoderm, i.e. the source of skeletal muscle
during embryogenesis (see Fig. 1). Approximately 10 % of
these cells were also able to participate in the formation of
hybrid myotubes when co-cultured with myoblasts (Barberi
et al. 2005). Efficient differentiation of ESCs into mesoderm
cells was achieved only when ESCs were co-cultured with
other mouse stromal cell line—PA6 (Udagawa et al. 1989)
in medium supplemented with RA and BMP-4 (Torres
et al. 2012). As mentioned before, both factors are engaged
in embryonic myogenesis. RA is involved in patterning of
the somites (Sirbu and Duester 2006) while BMP-4
promotes expansion of MPCs in dermomyotome by
delaying MRF expression (Pourquie et al. 1995). The
culture of mouse ESCs in the presence of RA, BMP-4, and
PA6 cells led to the generation of cells expressing the
myogenic marker—desmin (Torres et al. 2012). However,
expression of MRFs was not detected in cells obtained
using such experimental approaches (Torres et al. 2012).
Examples presented above show that PSCs are able to
undergo myogenic conversion only in fusion-dependent
manner (Archacka et al. 2014) or after initial differentiation
induced by stromal cell lines and/or myogenic regulators,
such as Wnt7a, BMP-4, and RA (Barberi et al. 2005;
Torres et al. 2012). Differences between PSCs and
adipose-derived stem cells or AC133 expressing cells, i.e.
those that are able to undergo myogenic differentiation in a
fusion-independent way, may reflect the fact that the latter
cells already express several myogenic markers—for
example Pax7 and Myf-5 (Torrente et al. 2004; Di Rocco
et al. 2006; Vieira et al. 2008). It should be also noted that
regenerative potential of ESCs co-cultured with myoblasts
was shown to be low. Bhagavati and Xu performed the
experiment during which ESCs expressing GFP were
transplanted into the muscle of mdx (murine X-linked
dystrophy) mice which lack dystrophin, one of the
structural proteins necessary for proper functioning of
skeletal muscle (Sicinski et al. 1989). GFP and dystrophin-
positive fibers were detected in the muscles of only two out
of eight mice transplated with cells, and one of these mice
had as few as 30 of these fibers (Bhagavati and Xu 2005).
Together, these results indicate that the co-culture system is
not efficient in the induction of myogenic differentiation of
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PSCs (Barberi et al. 2005; Bhagavati and Xu 2005;
Archacka et al. 2014). In addition, although the co-culture
system yields important information about myogenic
potential of stem cells and reciprocal interactions between
co-cultured cells, this method is not likely to be clinically
suitable. Many factors influencing stem cells which are
present in the medium or are released by cells co-cultured
with stem cells remain unknown. Identification of factors
that could direct differentiation of PSCs into functional
muscle cells is necessary for clinical implementation of
skeletal muscle cell therapy. This is a very challenging aim
as there are many potential inducers of stem cell myogenic
differentiation to be experimentally verified. Additionally,
designing such protocols requires precise determination of
proper doses and incubation time. Moreover, animal and
human PSCs most certainly will differ in their response to
selected factors (for review see Suwinska and Ciemerych
2011). Finally, PSCs propagated as EBs or cultured in
monolayer may also significantly vary (Osafune et al.
2008). Despite these obstacles, numerous growth factors,
cytokines, and small molecules have already been tested in
both EBs and monolayer-based PSC culture systems.
EB-based methods for myogenic differentiation
of PSCs
Within the first 3 days of differentiation, PSCs propagated
as EBs form three germ layers. The presence of ectoderm is
manifested by the expression of fibroblast growth factor 5
(FGF-5), endoderm by GATA-4, and mesoderm by
Brachyury (Leahy et al. 1999). Ryan and co-workers
showed that in EBs derived from human ESCs, factors
characteristic for MPCs such as Meox1, Pax3, and Pax7
can be detected approximately at 8th day of culture while
MRFs appear much later, i.e. after 39 days of culture (Ryan
et al. 2012). In a pioneering study by Rohwedel and
co-workers, MRF expression was detected in mouse ESCs
after 10 days of their differentiation within EBs (Rohwedel
et al 1994). However, Darabi et al. showed that level of
Pax3, Pax7, and MRF expression was extremely low in human
ESC-derived EBs even after 10 days of differentiation (Darabi
et al. 2008). Despite these differences between
experiments, the EB system was used in many studies,
including those describing derivation of the first myogenic
cells from mouse ESCs and iPSCs (Rohwedel et al. 1994;
Mizuno et al. 2010) and human ESCs (Zheng et al. 2006).
In many experiments involving EBs formation, medium
containing fetal bovine and/or horse serum was used
(e.g. Rohwedel et al. 1994; Zheng et al. 2006; Mizuno
et al. 2010). Although these studies yielded fundamental
information about PSC differentiation, it is known that
serum components may vary between batches and may
affect cell differentiation and also hamper experimental
reproducibility. Moreover, due to clinical requirements, a
robust differentiation protocol should be free of any animal
components which may pose a risk of contamination, with
unknown and/or undetected animal pathogens (for review
see Mannello and Tonti 2007; Unger et al. 2008). To
overcome this problem, serum-free media containing
defined components should be applied. The type of
medium may have a great influence on PSC differentiation.
For example, 4-day long culture of EBs in fetal bovine
serum-containing medium resulted in 77 % of cells
expressing Mixl1, the key regulator of gastrulation which is
crucial for endoderm and mesoderm formation (Hart et al.
2002; Pereira et al. 2012). Expression of this factor was
absent in EBs cultured in serum-free medium, and was
induced only when additional factors such as BMP4 and
Wnt3a were added to the medium (Gertow et al. 2013).
An additional important issue linked to the development
of the best differentiation protocol is the choice of PSC
differentiation stage at which cells are characterized by the
best therapeutic potential. With respect to the myogenic
differentiation of PSCs, cells at different stages of
differentiation, i.e. paraxial mesodermal cells, MPCs,
satellite cells, and myoblasts can be produced. Myogenic
cells at initial stages of differentiation, i.e. those expressing
Pax3 and/or Pax7, were shown to be characterized by higher
regenerative potential than cells that reached more advanced
stages of differentiation and started to express MRFs
(Montarras et al. 2005; Kuang et al. 2007; Rossi et al. 2010).
The production of myogenic progenitors can also be
enhanced by using genetic manipulation-free methods, for
example by culturing of EBs obtained from either mouse or
human ESCs in media containing a low RA concentration.
This experimental approach led to the elevation of Meox1
and Pax3 expression (Kennedy et al. 2009; Ryan et al.
2012). Derivation of progenitor cells that were able to
undergo terminal myogenic differentiation in vitro or
participate in muscle regeneration in vivo was also described
in other studies. Hwang and co-workers obtained cells
expressing PDGFaR, the marker of paraxial mesoderm,
and Awaya and colleagues generated Pax3/Pax7
expressing cells from human PSCs (Awaya et al. 2012;
Hwang et al. 2013). However, in both of these experiments
serum containing media and animal components were
used. Nevertheless, it should be underlined that such
studies provide data that were crucial for uncovering the
mechanisms of PSC differentiation and for development of
serum-free protocols for PSC myogenic differentiation. A
representative serum-free protocol was described in 2014
by Hosoyama and co-workers (Fig. 2). Human ESCs and
iPSCs were cultured in suspension, in medium supplemented
with epidermal growth factor (EGF) and fibroblasts growth
factor 2 (FGF-2). Under such conditions cells aggregated
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and formed free floating spheres, similar to EBs, but
described by the authors as EZ spheres (Hosoyama et al.
2014). After 6 weeks of culture 20 % of cells expressed
Pax7 and were able to undergo myogenic differentiation
and fuse during subsequent culture. Presence of FGF-2
was critical for derivation of myogenic progenitors since
no Pax7 expressing cells were generated when this factor
was omitted (Hosoyama et al. 2014). During embryonic
myogenesis FGF-2 prevents the differentiation of MPCs
into myoblasts, thus controlling the balance between the
number of progenitor and differentiating cells (Lagha et al.
2008). Next, EGF was shown to enhance the influence of
FGF-2 on differentiating PSCs. However, Hosoyama and
co-workers faced a problem connected to the fact that EZ
spheres, similar to EBs, are three-dimensional structures.
Thus, not all of the cells within these spheres receive the
signals at the same level. As a result, multiple cell types
can be formed. For example, EZ spheres cultured in the
presence of FGF-2 and EGF contained over 30 % of cells
expressing TuJ1, a marker of neural cells (Hosoyama et al.
2014).
In their excellent study Xu and co-workers examined
the influence of 2400 chemicals on zebrafish myogenesis.
As a result, they identified three factors, namely FGF,
forskolin, and a glycogen synthase kinase 3b (GSK3b)
inhibitor called BIO, which were shown to efficiently
induce myogenic differentiation of human iPSC (Xu et al.
2013). As mentioned above, FGF prevents premature
differentiation of MPCs during embryonic myogenesis
(Lagha et al. 2008). Forskolin increases cell proliferation
by activating adenylyl cyclase. GSK3b inhibits canonical
Wnt signaling pathway by targeting its transducer,
b-catenin, to degradation (for review see Wu and Pan
2010). As mentioned earlier Wnt signaling induces somites
formation and differentiation during vertebrate myogenesis,
and suppression of its activity inhibits mesoderm formation
Fig. 2 Selected methods for myogenic differentiation of PSCs.
Differentiation protocols based on the propagation of PSCs in
suspension (blue letters over the timelines) and in monolayer (purple
letters over the timelines) are shown. Information about factors used
for PSCs differentiation is indicated below the timelines. Cell types
used in studies are listed in the left column while differentiation
efficiency is described in the right column
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(Liu et al. 1999; Huelsken et al. 2000; Borello et al. 2006).
Wnt signaling is also essential for development of neural
tube and neural crest which provide important cues for
patterning of the paraxial mesoderm (Rios et al. 2011). EBs
formed from iPSCs were cultured in the presence of FGF,
forskolin, and BIO for 7 days (Fig. 2). Such conditions
resulted in a 200-fold increase in Pax7 expression and
60-fold induction of Myf-5 and MyoD expression, as
compared to control culture conditions (Xu et al. 2013). At
the same time the expression of ectoderm and endoderm
markers was not changed, indicating that such conditions
specifically induced myogenic differentiation of PSCs. More
importantly, transplantation of the factor-treated cells into
injured skeletal muscle showed that they are able to participate
in mouse muscle regeneration and colonize the satellite cell
niche, confirming their functionality (Xu et al. 2013).
Skeletal muscle is one of the most abundant tissues in
the body. Thus, large scale cell expansion is required to
generate adequate cell numbers for potential therapy or
tissue engineering. Although EBs serve as a good model in
basic research focused at PSC differentiation, this culture
system is rather laborious and time-consuming and does
not allow for generation of large quantities of differentiated
cells. However, EBs can be used as an intermediate step for
generation of myogenic cells from PSCs. Hwang and
co-workers have shown that cells differentiated in EBs and
sorted for PDGFaR could be successfully cultured in
monolayer and retained the ability to undergo terminal
myogenic differentiation despite several passages (Hwang
et al. 2013). Regardless of the EB use, it is the monolayer
culture that offers the possibility to generate a suitable
number of cells for clinical application.
Monolayer-based methods for myogenic
differentiation of PSCs
The first monolayer-based protocol for myogenic
differentiation of PSCs was described by Barberi and
co-workers in 2007. Human ESCs were cultured in medium
supplemented with insulin, transferrin, and selenium (ITS,
Barberi et al. 2007). After 35 days of culture, cells
expressing CD73, a marker of mesoderm and mesenchymal
stem cells, were selected. Similarly to mesenchymal stem
cells originating from bone marrow or adipose tissue, the
obtained CD73 expressing cells were able to undergo
adipogenic, chondrogenic, and osteogenic differentiation.
Moreover, up to 10 % of these cells were characterized by
the presence of myogenic markers such as Pax7 and MyoD.
Myogenic cells were selected from population of CD73
expressing cells on the basis of the presence of neural cell
adhesion molecule (NCAM), an adhesion protein expressed
by differentiating myoblasts (Walsh and Ritter 1981).
Next, culture in N2 medium, which enhances myoblasts
maturation, induced NCAM expressing cells to synthesize
myogenin and structural muscle proteins such as skeletal
muscle actin and sarcomeric myosin, and to form myotubes
(Barberi et al. 2007). This protocol did not require genetic
modification, but it was lenghty and needed repetitive
cell sorting. Moreover, it also involved culture in
serum-containing media which was disadvantageous in
terms of its future use in cell therapies.
Significant progress has been made by Sakurai and
co-workers who designed a serum-free protocol resulting in
the derivation of paraxial mesodermal cells, i.e. the material
for further myogenic differentiation, from mouse and human
ESCs and iPSCs (Sakurai et al. 2009, 2012). Differentiation
of PSCs into paraxial mesodermal cells was achieved by
supplementation with Activin A, a member of the TGFb
family of proteins, which prevented cell apoptosis and
enhanced the expression of Brachyury and Mixl1, followed
by supplementation with BMP4 that enhanced cell
proliferation, and finally LiCl. LiCl activated the Wnt
signaling pathway and induced expression of paraxial
mesoderm markers, such as Tbx6 and PDGFaR. Paraxial
mesoderm cells obtained according to this protocol were
able to undergo in vitro myogenic differentiation, manifested
by the presence of myogenin and myosin heavy chain (MHC),
which are markers of differentiated myoblasts, myotubes, and
myofibers. Importantly, these cells also participated in muscle
reconstruction in vivo (Sakurai et al. 2012).
Numerous studies have focused on the myogenic
differentiation of mouse and human iPSCs (Mizuno et al.
2010; Darabi et al. 2011b; Goudenege et al. 2012; Tanaka
et al. 2013; Abujarour et al. 2014; Maffioletti et al. 2015;
Shoji et al. 2015). Many of these are based on MyoD
overexpression, a method initially described for myogenic
conversion of fibroblasts as well as neural, fat, and liver cells
(Weintraub et al. 1989). Introduction of MyoD to iPSCs
resulted in the derivation of myogenic cells with the
efficiency as high as 90 % (Goudenege et al. 2012; Tanaka
et al. 2013; Abujarour et al. 2014; Maffioletti et al. 2015;
Shoji et al. 2015). Availability of myogenic cells derived
from human iPSCs also provides opportunity for individu
alized patient therapy. However, it should be noted that in
case of inherited skeletal muscle diseases such as muscular
dystrophies, effective autologous cell transplantation will
require genetic correction of the initial defect prior to
transplantation. It has been shown that introduction of a
human artificial chromosome with a complete dystrophin
sequence into iPSCs derived from DMD patients or mdx
mice led to their successful genetic correction (Kazuki et al.
2010). Similarly, Tedesco and co-workers showed that
genetic correction of iPSCs derived from patients suffering
from limb-girdle muscular dystrophy 2D caused by mutation
in the gene encoding a-sarcoglycan can be efficiently corrected
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in vitro with a lentiviral vector carrying the gene encoding
human a-sarcoglycan (Tedesco et al. 2012). Transplantation
of genetically corrected cells into a-sarcoglycan-null mice
resulted in the formation of myofibers expressing this
protein (Tedesco et al. 2012). An important step towards the
future treatment of muscular dystrophies using genetically
corrected autologous iPSCs has been made by Filareto and
co-workers. In this study iPSCs were derived from
fibroblasts isolated from dystrophin and utrophin double
knockout mice that are characterized by progressive muscle
wasting, impaired mobility, and other symptoms resembling
indicants of human DMD (Deconinck et al. 1997; Grady
et al. 1997). Genetic correction of iPSCs was obtained by
introduction of a micro-utrophin gene which complements
the lack of both dystrophin and utrophin (Sonnemann et al.
2009) using Sleeping Beauty transposon which enables
efficient and stable gene transfer with limited risk of
insertional mutations (Yant et al. 2005). Next, myogenic
progenitors were obtained from genetically corrected
iPSCs by overexpression of Pax3 and Pax7.
Transplantation of PDGFaR expressing cells to dystrophin
and utrophin double knockout mice resulted in the
restoration of dystrophin-glycoprotein complex and the
improvement of muscle contractile properties. Importantly,
transplanted cells were able to seed the compartment of
satellite cells and participate in the subsequent regeneration
of the engrafted muscle. In addition, myogenic progenitors
derived from genetically corrected iPSCs were also able to
migrate and engraft different muscles after systemic
transplantation (Filareto et al. 2013).
Despite unquestioned achievements in the field, it is still
necessary to improve existing protocols by introducing
iPSCs reprogramming factors or genes promoting myogenic
differentiation of PSCs with non-integrating methods, while
simultaneously retaining the efficiency of cell conversion.
Moreover, although genetically modified cells can currently
be used as cellular models in research focused on skeletal
muscle disease modelling and drug discovery, it should be
noted that their differentiation may not necessarily reflect
typical myogenic specification or disease development and
progression. Thus, the protocols that guide the differentiation
of PSCs through the key milestones of myogenesis, i.e.
paraxial mesoderm formation, somitogenesis, dermomyotome
development, differentiation of MPCs, myoblasts and
myotubes, are desired. Recently, the protocol for PSC
myogenic differentiation, recapitulating essential steps of
myogenesis, has been described (Chal et al 2015).
Activation of Wnt signalling followed by inhibition of
BMP-4 resulted in conversion of PSCs into striated
myofibers which were accompanied by Pax7-positive cells.
Transplantation of Pax7-positive cells to mdx mice resulted
in dystrophin expression and colocalization of satellite cell
niche in engrafted muscles (Chal et al 2015). Earlier, two
other multi-step protocols based on embryonic myogenesis
were proposed (Borchin et al. 2013; Shelton et al. 2014;
Fig. 2). Both of them start with the activation of Wnt
signaling as a first step to induce mesodermal differentiation
of PSCs. Excellent studies by Skerjanc and co-workers
revealed that the inhibition or loss of b-catenin, the main
transducer of canonical Wnt signaling, decreases myogenic
differentiation of PSCs (Petropoulos and Skerjanc 2002;
Wong et al. 2013). Such a phenotype results from the loss
of Meox1, Six1, Foxc1, Foxc2, Pax3, and Pax7, which are
expressed in mesoderm, somites, and MPCs (Williams and
Ordahl 1994; Reijntjes et al. 2007; Kennedy et al. 2009;
Savage et al. 2010). Mouse and human ESCs cultured in
the presence of GSKb3 inhibitor, followed by FGF-2
treatment and culture in N2 medium, underwent efficient
myogenic differentiation (Shelton et al. 2014; Fig. 2).
Inhibition of GSKb3 was critical for Brachyury upregulation.
After 2 days of culture over 90 % of differentiating ESCs
expressed this mesodermal marker. Further expansion of
such cells resulted in efficient specification and
differentiation of myogenic cells, for example over 40 % of
cells expressed Pax7, a marker of MPCs, while another
47 % of cells expressed MHC, a marker of differentiated
myoblasts and myotubes (Shelton et al. 2014; Fig. 2).
Another protocol proposed a similar approach, i.e. inhibition
of GSKb followed by FGF-2 treatment (Borchin et al.
2013; Fig. 2). Such treatment induced expression of Pax3
and Pax7 in 20 % of differentiating PSCs (Borchin et al.
2013; Fig. 2). The isolation of myogenic progenitors from
the whole population of differentiating PSCs was achieved
on the basis of c-met and CXCR4 expression, proteins that
are highly expressed during migration of MPCs within the
embryo (Vasyutina et al. 2005) as well as muscle specific
acetylcholine receptor (ACHR), which is required for
neuromuscular junction formation (Brehm and Henderson
1988). Over 90 % of cells expressing c-met, CXCR4, and
ACHR synthesized Pax3 and Pax7 and underwent myogenic
differentiation as manifested by MRF expression and
myotube formation (Borchin et al. 2013). Thus, two
protocols based on manipulation of Wnt signaling levels
and involving FGF-2 treatment led to the efficient
myogenic differentiation of mouse and human ESCs as
well as human iPSCs (Borchin et al. 2013; Shelton et al.
2014). However, the functionality of the obtained
myogenic cells has not been tested in vivo. The question
of whether these cells can give rise not only to mature
myoblasts, myotubes, and myofibers, but also settle
satellite cells niche remains unanswered. It is worthy to
note that both protocols included chemically defined
media, therefore they should be replicable and controlled.
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Conclusions
Substantial progress has been made in the development of
efficient and safe protocols for myogenic differentiation of
PSCs. Protocols based on knowledge concerning embryonic
myogenesis provided favorable in vitro conditions for
robust differentiation of PSCs into myogenic cells. How
ever, there are still a few challenges, already mentioned in
this review, that need to be overcome in regard to clinical
application of PSC based therapy for dysfunctional skeletal
muscle. Among these are: (1) elimination of any animal
components used for culture and differentiation of PSCs,
(2) selection of the cells characterized by the best thera-
peutic potential, i.e. able to efficiently migrate and engraft
different groups of muscles after systemic transplantation
as well as to seed the satellite cell niche and participate in
subsequent regeneration of the settled muscle, (3) generation
of large number of functional myogenic cells, influencing
contractile properties of treated muscles, (4) derivation of
clinically safe cells, characterized by genome stability after
reprogramming or genetic correction. Since PSCs have the
potential to form teratomas, it is very important to indicate
the suitable set of markers for precise depletion of
insufficiently differentiated cells and selection of clinically
safe ones. Successful PSC-based therapy will also require
limiting the risk of immune response to PSC derivatives.
Although PSCs display some level of immuno privilege as
they express low levels of major histocompatibility
complex (MHC)I, lack MHCII and co-stimulatory
molecules, it is currently clear that both undifferentiated
ESCs and iPSCs, as well as their derivatives, can be
rejected after transplantation into an immune-competent
recipient (for review see Imberti et al. 2015). Experiments
performed with the use of humanized mice reconstituted
with a functional human immune system revealed that even
in case of autologous transplantation, iPSCs can induce an
immune response leading to cell rejection (Zhao et al.
2015). It is caused by elevated expression of immunogenic
antigens such as Zg16 (Zhao et al. 2011). Although
development of PSC-based therapy for dysfunctional
skeletal muscle may still seem to be challenging, the recent
achievements in the field are promising and have already
led to significant progress in this protocol optimalization.
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